Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01784614
Other study ID # 12662
Secondary ID I2K-JE-ZZAW
Status Completed
Phase Phase 1
First received February 4, 2013
Last updated December 22, 2015
Start date September 2009
Est. completion date March 2010

Study information

Verified date December 2015
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods. Participants will receive a single dose of LY2624803 or placebo in each treatment period.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria:

- Overtly healthy males or female Japanese

- Women of child-bearing potential, who test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug

- Body mass index (BMI) of 17.6 to 26.4 kilogram per meter square (kg/m^2), inclusive

- Normal bedtime hours, with routine time spent in bed between 6.5 hours and 9 hours each night

- Clinical laboratory test results within normal reference range

- Venous access sufficient to allow blood sampling as per the protocol

- Are reliable and willing to make themselves available for the duration of the study and are willing and able to follow study procedures

- Have given written informed consent approved by Lilly and the ethical review board governing the site

Exclusion Criteria:

- Within 4 months of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication

- Persons who have previously completed or withdrawn from this study or any other study investigating LY2624803 after receiving study drug

- Known allergies to LY2624803 or related compounds

- Women who are lactating

- Shift workers [those who shifted or plan to shift work within 7 days of any phase advance polysomnography (PSG) night] or any person who has crossed (or will have crossed) more than one time zone by aircraft within 3 days prior to entry

- Have an irregular or altered sleep/wake schedule that is likely to prevent from keeping a regular sleep/wake schedule during the study

- Regular napping (= 2 daytime naps/week by history)

- Extreme morning type or evening type

- Rhinitis, conjunctivitis, urticaria or chronic pain severe enough to interfere with sleep

- Nocturia that would interfere with sleep assessment

- Symptoms consistent with a sleep disorder or history of same

- Evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months that could contribute to insomnia

- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurocardiogenic or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data

- History or presence of orthostatic signs and symptoms within 2 years

- History of seizure or a close relative having a seizure disorder (such as epilepsy). History of a single febrile convulsion more than 10 years ago is acceptable. History of cranial trauma and loss of consciousness will be discussed prior to including any such participant

- Abnormal movements observed outside of normal sleep time

- Abnormal supine blood pressure and/or pulse rate

- Participants with orthostatic hypotension at screening

- An abnormality in the 12-lead electrocardiogram (ECG) that increases the risks associated with participating in the study

- Regular use of known drugs of abuse and/or positive findings on urinary drug screening

- Evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies

- Evidence of hepatitis C and/or positive hepatitis C antibody

- Evidence of hepatitis B and/or positive hepatitis B surface antigen

- Evidence of syphilis infection and/or positive syphilis test

- Use or intended use of prescription (except oral contraceptives), over-the-counter or herbal medication, specifically antihistamines, anticholinergic medications or any medications that affect sleepiness, within 28 days prior to Period 1 dosing and/or during the study

- Participants who have donated more than 200 milliliters (mL) of blood or component blood within one month of screening, or those who have donated more than 400 mL of blood within 3 months of screening

- History of smoking within the previous 6 months of screening

- Participants who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or participants unwilling to stop alcohol consumption for the period

- Participants whose daily caffeine intake does not permit maintenance of usual sleep/wake schedule

- No response to phase advance or a placebo responder

- Sleep disorders detected during the PSG screening night

- History or presence of breast cancer

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)


Related Conditions & MeSH terms

  • Sleep Initiation and Maintenance Disorders

Intervention

Drug:
LY2624803 - Solution
Administered orally as reconstituted solution
LY2624803 - Capsule
Administered orally as a capsule
Placebo - Solution
Administered orally as solution
Placebo - Capsule
Administered orally as a capsule

Locations

Country Name City State
Japan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sagamihara

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo WASO was calculated as total time in awake epochs between sleep onset time (first stage 2 epoch) and the end of the primary recording period (8 hours after lights -off). Data presented are Geometric Least Squares (LS) means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants. 8 hours in Periods 1, 2 and 3 No
Secondary Latency to Persistent Sleep (LPS) LPS is defined as the latency from the lights-off time to the first stage 2 sleep followed by at least 10 consecutive minutes of sleep epochs. Data presented are Geometric LS means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants. 8 hours in Periods 1, 2 and 3 No
Secondary Total Sleep Time (TST) TST is defined as the total time in sleep epochs from sleep onset time to the end of the primary recording period (8 hours after lights -off). LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants. 8 hours in Periods 1, 2 and 3 No
Secondary PK: Maximum Plasma Concentration (Cmax) of LY2624803 After Single Oral Dose in Period 4 Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, 12, 18, and 42 hours post-dose in Period 4 No
Secondary PK: Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-8)] of LY2624803 After Single Oral Dose in Period 4 Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, 12, 18, and 42 hours post-dose in Period 4 No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Recruiting NCT05000528 - Evaluation of the Effectiveness of Patient Therapeutic Education on Chronic Insomnia N/A
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT00365261 - Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer Phase 4
Completed NCT00380003 - Efficacy Study of EVT 201 to Treat Insomnia Phase 2
Completed NCT00183378 - Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease N/A
Completed NCT00097604 - Effects of Valerian on Sleep in Healthy Older Adults Phase 2
Completed NCT00946530 - Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease N/A
Completed NCT00630175 - Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia Phase 3
Completed NCT00044629 - Combined Behavioral/Pharmacological Therapy for Insomnia Phase 2
Completed NCT00079664 - Comparing Tai Chi Training to a Low-Stress Physical Activity to Enhance Sleep in Older Adults Phase 1
Completed NCT01154023 - Behavioral Intervention for Insomnia in Older Adults N/A
Recruiting NCT04417153 - Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Recruiting NCT04986007 - Addressing Nocturnal Sleep/Wake Effects on Risk of Suicide in Older Adults N/A
Completed NCT03852966 - Better Sleep in Psychiatric Care - ADHD Pilot Study N/A
Terminated NCT00750919 - Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) Phase 3
Recruiting NCT04550507 - Mind-Body Interventions to Mitigate Effects of Media Use on Sleep in Early Adolescents N/A
Recruiting NCT05226585 - Mechanisms of Change in Cognitive Behavioral Therapy for Insomnia (CBTi) N/A